Nano-enabled natriuretic peptide therapy in post-myocardial infarction heart failure: from functional NP deficiency to dual-axis (cGMP-dependent and -independent) cardioprotection.
Myocardial infarction (MI) remains a major driver of incident heart failure (HF) despite timely reperfusion and guideline-directed medical therapy. Current treatments, largely centered on neurohormonal blockades, attenuate maladaptive pathways but do not restore endogenous cardioprotective systems. Among these, the nat...